Describing 2016 as "a year of significant transformation", Takeda Pharmaceutical Co. Ltd. president and CEO Christophe Weber cautioned that while much has already been achieved in the Japanese company’s turnaround strategy, this "will take many years to deliver" in full.
For now, the "focus is on sustained sales growth" driven by Takeda's three chosen core therapeutic areas of gastrointestinal, oncology...








